|
 AZD9291, which the company expects to file for U.S. approval in the
second quarter of 2015, is one of a number of cancer medicines
AstraZeneca is hoping will rebuild its sales following patent losses
on older drugs.
An analysis presented at the European Lung Cancer Conference in
Geneva demonstrated a median progression-free survival for patients
on the drug of 13.5 months.
AZD9291, like a rival product in development at Clovis Oncology,
targets a genetic mutation that helps tumors evade current lung
cancer pills, including AstraZeneca's own established product Iressa.
During its defense against a $118 billion takeover attempt by Pfizer
last year, AstraZeneca said it believed AZD9291 could sell as much
as $3 billion a year.
(Reporting by Ben Hirschler. Editing by Jane Merriman)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
|
